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The exact location of origin for giant cell tumors of bone (GCTB) remains controversial, as lesions are not routinely imaged early
but rather late when the tumor is large and clinically symptomatic. At the time of diagnosis, GCTB are classically described as
lucent, eccentric lesions with nonsclerotic margins, located within the epiphysis to a greater extent than the metaphysis. Here we
present a case of a biopsy proven GCTB initially incidentally seen on MRI as a small strictly metaphyseal lesion, which over the
course of several years expanded across a closed physis to involve the epiphysis and abut the articular surface/subchondral bone
plate.
1. Introduction
Giant cell tumors of bone (GCTB) are relatively common
tumors, accounting for 5% of all primary bone tumors [1].
GCTB most commonly affect the long bones with 50–65%
affecting the knee [1, 2]. Patients with GCTB usually present
in their 20 s or 30 s with nonspecific symptoms such as pain,
soft tissue swelling, and decreased range of motion at the
adjacent joint [3]. The typical radiographic appearance is
a lytic lesion without matrix; CT shows a mostly narrow
but sometimes wider zone of transition. Margins are usually
nonsclerotic and the location is eccentric extending to the
subchondral bone. The exact site of origin of GCTB remains
controversial, but it is thought that the lesion arises from the
metaphyseal side of the epiphyseal plate [1, 4]. However, 84–
99% of lesions extend to within 1 cm of articular surface at the
time of imaging,making exact localization of the site of origin
difficult to assess [4].We present a unique case of aGCTB that
is profiled over 4 years by imaging and shown to arise at the
metaphysis and subsequently expand into the epiphysis and,
ultimately, abut the articular surface.
2. Case Report
A25-year-oldman initially presented to an outside institution
in 2011 with a history of a right knee hyperextension injury
while playing basketball. He was evaluated with a right knee
MRI that showed an anterior cruciate ligament (ACL) tear
and a small subcortical lesion at the posterior aspect of the
medial metaphysis of the distal femur that was nonspecific
and too small to characterize; however, enthesopathy and
small cortical based lesions such as nonossifying fibroma,
enchondroma, fibrous cortical defect, and fibrous dysplasia
were included in the differential diagnosis (Figure 1). He
underwent successful ACL reconstruction and recovered
well, returning to normal activities. Two years later radio-
graphs were obtained when he developed right knee pain;
he was clinically diagnosed with a medial cruciate ligament
(MCL) sprain and was referred to physical therapy. His pain
continued for several months despite therapy. He switched
health insurance coverage and was lost to follow-up but re-
presented to our institution in 2015 with persistent right knee
pain. Radiographs and an MRI were obtained.
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(a) (b)
Figure 1: MRI coronal (a) and sagittal (b) T2 fat saturation images at initial presentation for right knee pain status after hyperextension in
2011. The arrows indicate a round T2 heterogeneous but mostly hypointense subcortical intraosseous lesion arising in the posterior aspect of
the medial distal femoral metaphysis. There was also a complete ACL tear and knee joint effusion.
(a) (b)
Figure 2: Frontal view radiographs of the right knee obtained (a) 2 years and (b) 4 years after initial imaging demonstrate a closed physis
with progressive enlargement of a well-circumscribed, nonsclerotic, eccentric lucent lesion, as indicated by the arrows, at the medial femoral
condyle abutting the articular surface.
The radiographs obtained in 2013 and 2015, two and four
years, respectively, after the metaphyseal lesion was seen on
the initial MRI, showed a well-marginated, locally aggressive,
eccentric lesion in the right medial femoral condyle extend-
ing from the metaphysis to the epiphysis (Figure 2). MRI
demonstrated amarked increase in size of this now expansile,
multilobulated right medial femoral condylar lesion with
fluid-fluid levels extending to the subchondral bone plate
(Figure 3).
Differential diagnosis at this time was more limited and
suggestive of GCTB based on age, location, and radiological
criteria; however, aneurysmal bone cyst (ABC) and malig-
nant tumors such as telangiectatic osteosarcoma or clear cell
chondrosarcoma remained as alternative diagnoses. A total
body bone scan was performed, demonstrating intense
uptake in the right medial femoral condyle without other
lesions identified (Figure 4). The patient was referred to
orthopedics in late 2015 and an incisional biopsy and frozen
section were performed, followed by immediate curettage,
burring, hydrogen peroxide application, argon beam, and
cement packing.
Macroscopic examination of the curettage specimen
showed multiple, irregular fragments of rubbery, red-tan soft
tissue, and white-tan hard osteocartilaginous tissue. Micro-
scopic examination revealed blood-filled spaces lined by
fibrous septa without an endothelial lining or vascular
smooth muscle. The fibrous septa contained scattered multi-
nucleated giant cells, abundant hemosiderin, osteoid matrix
Case Reports in Radiology 3
(a) (b)
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Figure 3:MRI of the right knee 4 years after initial presentation demonstrates an expansilemultilobulatedmass in themedial femoral condyle.
(a) Coronal T2 turbo spin echo (TSE) short tau inversion recovery (STIR), (b) sagittal T2 TSE fat saturation, and (c) coronal and (d) sagittal
T1 TSE fat saturation images demonstrating marked interval increase in size of a T1 and T2 heterogeneous multilobulated, expansive osseous
lesion, as indicated by the arrows, extending from the posterior distal medial femoral metaphysis to the medial femoral epiphysis. Within this
mass are multiple fluid filled spaces with fluid-fluid levels suggestive of intralesional secondary aneurysmal bone cyst formation.
or reactive bone, and spindled mononuclear cells with plump
nuclei without hyperchromasia or significant increase in
mitoses, consistent with an aneurysmal bone cyst (ABC)
component (Figure 5(a)). In addition, many areas without
fibrosis but with evenly distributed multinucleated giant cells
amid plump to spindled mononuclear cells were identified,
raising the possibility of GCTB (Figure 5(b)). Fluorescence
in situ hybridization (FISH) testing for the USP6 gene rear-
rangement, characteristic of primary ABC [5], was negative
in this case, further supporting the impression of secondary
ABC superimposed on GCTB.
The patient has had an uncomplicated postoperative
course: at 6 months after surgery, he has returned to pain-
free, full activity, and postoperative radiographs showed no
evidence of local recurrence.
3. Discussion
GCTB is characterized by the most recent World Health
Organization classification as a benign but locally aggressive
tumor [6]. Histologically, the tumor consists of numerous
osteoclast-like multinucleated giant cells, evenly distributed
amongst round to spindled mononuclear cells [1]. Although
aggressive intralesional treatment results in an acceptably low
local recurrence rate, GCTB can recur locally after surgical
excision and can metastasize, most commonly to the lungs
[4]. Malignancy has also been described in GCTB, with
primary malignancy referring to cases with areas consistent
with a high-grade sarcoma present within otherwise con-
ventional GCTB and secondary malignant referring to cases
of high-grade sarcoma occurring at the site of previously
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Figure 4: 25mCi technetium total bone scan demonstrating intense uptake in right medial femoral condyle consistent with osseous turnover
in the region of the expansile mass, as indicated by the arrows. No other lesions were noted.
(a) (b)
Figure 5: Microscopic examination of curettage specimen. (a) Aneurysmal bone cyst-like area with blood-filled spaces lined by fibrous
septa containing reactive bone (blue arrows) and hemosiderin (green arrow head); H&E stain at 40x and at 400x (b) demonstrating giant
cell tumor areas with multinucleated giant cells evenly dispersed amongst mononuclear cells with spindled morphology. No overt or diffuse
nuclear pleomorphism is identified and while scattered mitotic figures are present (arrow head), no atypical forms are seen.
treated GCTB [6, 7]. GCTB’s typical radiographic findings
include a well-defined, expansile, and eccentrically located
lucent lesion with a narrow zone of transition but a non-
sclerotic margin. MRI findings are nonspecific but classically
reveal increased signal intensity on fluid sensitive sequences,
decreased signal intensity on fat sensitive sequences, and
enhancement on postcontrast imaging [1, 8]. Findings are
often heterogeneous due to hemosiderin deposition as well
as bone and collagen as was noted in our case.
In our patient, initial incidental MRI characterization
was nonspecific and showed a small T1 hypointense and T2
heterogeneous subcortical intraosseous metaphyseal lesion.
Follow-up radiographs 3 years later displayed the more typi-
cal radiographic features described above (Figure 3).
Differential diagnosis included ABC which can be a
primary, de novo neoplasm characterized by rearrangements
of the USP6 gene, or secondary, arising in association with
other benign ormalignant tumors, including GCTB. Primary
and secondary ABCs have a similar appearance radiograph-
ically and pathologically, and the diagnosis of GCTB with
secondary ABC formation is typically confirmed withmicro-
scopic evaluation. Radiographically, ABC is more commonly
characterized by a sclerotic margin, typically occurs in
younger patients compared to GCTB, and often manifests
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fluid-fluid levels without other soft tissue components [9].
Rare primary bone malignancies such as clear cell chon-
drosarcoma and giant cell rich osteosarcoma can also mimic
GCTB but often have more destructive features, adjacent
bone marrow edema, and/or a soft tissue mass component.
Treatment for GCTB is traditionally surgical with curet-
tage and cement packing. However, the local recurrence
rate has been reported to be as high as 25% depending
on anatomical location [10, 11]. Postoperative radiographs
obtained must be closely inspected for new lucencies at the
cement bone interface. Recently, the monoclonal antibody
drug denosumab has been successfully used to treat GCTB
by inhibiting the osteoclastic activity of cells in GCTB.
Medical therapy alone with denosumab has been reported
to have a dramatic treatment response rate of up to 90%
tumor necrosis, with increased sclerosis and reconstitution
of cortical bone [12]. This response suggests that denosumab
is an effective treatment to reduce tumor size preoperatively,
to treat lesions that cannot be treated surgically, or for those
patients for whom surgery is not an option.
While GCTB is classically described as abutting an artic-
ular surface, its location of origin remains somewhat con-
troversial in the literature. GCTB most often presents in a
skeletally mature patient with pain and at the time of initial
imaging primarily involves the epiphysis [8]. However, the
largest study to date of GCTB in skeletally immature patients
described up to 96% of cases to be localized to themetaphysis
[13]. The metaphysis is rich in osteoclasts and highly vascu-
larized. Perhaps the increased cell turnover and proliferation,
with the resultant increase in possible mutations, explains
the metaphyseal origin for GCTB in young adults. Our case
report reinforces these findings and the hypothesis that these
tumors originate in the metaphysis and migrate towards
the epiphysis after closure of the physis. This distinction is
important as GCTB should be included in the differential for
a metaphyseal lesion to facilitate early diagnosis.
In summary, to the best of our knowledge, this is the first
case to clearly demonstrate multiple modalities of the unique
progression of a pathologically confirmed GCTB in a single
patient over four years from its origin in the metaphysis to its
final eccentric location abutting an articular surface.
Consent
Informed written consent was obtained.
Competing Interests
The authors declare that they have no competing interests.
References
[1] C. J. Chakarun, D. M. Forrester, C. J. Gottsegen, D. B. Patel, E.
A. White, and G. R. Matcuk, “Giant cell tumor of bone: review,
mimics, and new developments in treatment,” RadioGraphics,
vol. 33, no. 1, pp. 197–211, 2013.
[2] W. S. Hong, M. S. Sung, J.-H. Kim et al., “Giant cell tumor with
secondary aneurysmal bone cyst: a unique presentation with
an ossified extraosseous soft tissuemass,” Skeletal Radiology, vol.
42, no. 11, pp. 1605–1610, 2013.
[3] B. Ghostine, A. Sebaaly, and I. Ghanem, “Multifocal metachro-
nous giant cell tumor: case report and review of the literature,”
Case Reports in Medicine, vol. 2014, Article ID 678035, 8 pages,
2014.
[4] M. D. Murphey, G. C. Nomikos, D. J. Flemming, F. H. Gannon,
H. T. Temple, and M. J. Kransdorf, “Imaging of giant cell
tumor and giant cell reparative granuloma of bone: radiologic-
pathologic correlation,” Radiographics, vol. 21, no. 5, pp. 1283–
1309, 2001.
[5] A. M. Oliveira and M. M. Chou, “USP6-induced neoplasms:
the biologic spectrum of aneurysmal bone cyst and nodular
fasciitis,” Human Pathology, vol. 45, no. 1, pp. 1–11, 2014.
[6] C. D. M. Fletcher, J. A. Bridge, P. Hogendoorn, and F. Mertens,
“Giant cell tumour,” in WHO Classification of Tumour of Soft
Tissue and Bone, pp. 321–324, WHO, 4th edition, 2013.
[7] F. Bertoni, P. Bacchini, and E. L. Staals, “Malignancy in giant cell
tumor of bone,” Cancer, vol. 97, no. 10, pp. 2520–2529, 2003.
[8] G. Akaike, T. Ueno, S. Matsumoto, N. Motoi, and K. Matsueda,
“Rapidly growing giant cell tumor of bone in a skeletally
immature girl,” Skeletal Radiology, vol. 45, no. 4, pp. 567–573,
2016.
[9] M. J. Kransdorf and D. E. Sweet, “Aneurysmal bone cyst: con-
cept, controversy, clinical presentation, and imaging,”American
Journal of Roentgenology, vol. 164, no. 3, pp. 573–580, 1995.
[10] K. Kafchitsas, B. Habermann, D. Proschek, A. Kurth, and C.
Eberhardt, “Functional results after giant cell tumor operation
near knee joint and the cement radiolucent zone as indicator of
recurrence,” Anticancer Research, vol. 30, no. 9, pp. 3795–3799,
2010.
[11] R. J. O’Donnell, D. S. Springfield, H. K. Motwani, J. E. Ready,
M. C. Gebhardt, and H. J. Mankin, “Recurrence of giant-cell
tumors of the long bones after curettage and packing with
cement,” Journal of Bone and Joint Surgery A, vol. 76, no. 12, pp.
1827–1833, 1994.
[12] D. Thomas, R. Henshaw, K. Skubitz et al., “Denosumab in
patients with giant-cell tumour of bone: an open-label, phase
2 study,”The Lancet Oncology, vol. 11, no. 3, pp. 275–280, 2010.
[13] M. J. Kransdorf, D. E. Sweet, P. C. Buetow, M. A. I. Giudici, and
R. P. Moser, “Giant cell tumor in skeletally immature patients,”
Radiology, vol. 184, no. 1, pp. 233–237, 1992.
